Tuesday, April 24, 2018 4:53:03 PM
This case is unusual though.
In their recent SEC filings, NNVC says they only have enough money to continue current operations for another nine months. That's excluding any costs for work required to take a candidate into IND testing.
Yet investors are choosing to ignore this dire situation as disclosed by the company itself.
On top of this, the CEO has jumped ship right at this critical moment for raising funds. He did that without even finding a replacement, leaving Diwan as the CEO, President, and Chairman of the board. Diwan is also the major shareholder of Theracour, who receives almost the entirety of every penny NNVC spends. This egregious conflict of interest further negates any possibility the company has for raising additional funds.
Investors are frozen, and pretending as if their investment isn't going to vanish in less than a year.
In their recent SEC filings, NNVC says they only have enough money to continue current operations for another nine months. That's excluding any costs for work required to take a candidate into IND testing.
Yet investors are choosing to ignore this dire situation as disclosed by the company itself.
On top of this, the CEO has jumped ship right at this critical moment for raising funds. He did that without even finding a replacement, leaving Diwan as the CEO, President, and Chairman of the board. Diwan is also the major shareholder of Theracour, who receives almost the entirety of every penny NNVC spends. This egregious conflict of interest further negates any possibility the company has for raising additional funds.
Investors are frozen, and pretending as if their investment isn't going to vanish in less than a year.
A casual stroll through the lunatic asylum shows that faith does not prove anything. Friedrich Nietzsche
Recent NNVC News
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/01/2025 09:07:54 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/29/2025 08:33:17 PM
